PI-RADS-Based Segmented Threshold of PSMA-PET SUVmax Is Better than Traditional Fixed Threshold for Diagnosing Clinically Significant Prostate Cancer Especially for PI-RADS 3 Lesions

被引:3
|
作者
Meng, Xiaoli [1 ]
Ma, Wenhui [1 ]
Zhang, Jingliang [2 ]
Quan, Zhiyong [1 ]
Zhang, Mingru [1 ]
Ye, Jiajun [1 ]
Shu, Jun [3 ]
Ren, Jing [3 ]
Qin, Weijun [2 ]
Kang, Fei [1 ]
Wang, Jing [1 ]
机构
[1] Fourth Mil Med Univ, Xijing Hosp, Dept Nucl Med, Xian, Peoples R China
[2] Fourth Mil Med Univ, Xijing Hosp, Dept Urol, Xian, Peoples R China
[3] Fourth Mil Med Univ, Xijing Hosp, Dept Radiol, Xian, Peoples R China
基金
中国国家自然科学基金;
关键词
Prostate-specific membrane antigen; Positron emission tomography; Multi-parametric MRI; Prostate cancer; GA-68-PSMA PET/CT; MULTIPARAMETRIC MRI; VALIDATION; ACCURACY; BENIGN; TRUS; ISUP;
D O I
10.1007/s11307-023-01841-6
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
ObjectivesOur purpose was to compare the performance of prostate-specific membrane antigen (PSMA)-positron emission tomography (PET) traditional fixed threshold (FT) and newly established Prostate Imaging Reporting and Data System (PI-RADS)-based segmented threshold (ST) for diagnosing clinically significant prostate cancer (csPCa).MethodsThe study retrospectively included 218 patients who underwent multiparametric magnetic resonance imaging (mpMRI) and PSMA-PET examination for suspected prostate cancer (PCa) from January 2018 to November 2021. Lesions with Gleason score & GE; 3 + 4 were diagnosed as csPCa. In PSMA-PET maximum standardized uptake value (SUVmax), the FT for all the lesions and STs for lesions with different PI-RADS score for diagnosing csPCa were determined by receiver operating characteristic (ROC) curves analysis and compared with Z test. The McNemar test was used to compare sensitivity and specificity.ResultsAmong the 218 patients, there were 113 csPCa and 105 non-csPCa. The PSMA-PET FT was SUVmax > 5.3 (area under the curve, AUC = 0.842) and STs for PI-RADS 3/4/5 were SUVmax > 4.2/5.7/6.0 (AUCs = 0.870/0.867/0.882), respectively. The AUC of PSMA-PET ST was higher than that of PSMA-PET FT (0.872 vs. 0.842), especially for PI-RADS 3 (0.870 vs. 0.653). Multimodality diagnostic criteria combining PSMA-PET ST and PI-RADS scores of mpMRI was established and its AUC was higher than that of PSMA-PET ST (0.893 vs. 0.872) and significantly higher than that of PSMA-PET FT (0.893 vs. 0.842) with an improvement in sensitivity (93% vs. 78%, p < 0.05) without significantly sacrificing specificity (86% vs. 91%, p > 0.05).ConclusionsFor diagnosing csPCa, PI-RADS-based PSMA-PET segmented threshold achieved better performance than traditional fixed threshold, especially for PI-RADS 3 lesions. Multimodality diagnostic criteria demonstrated higher diagnostic performance than segmented threshold and significantly better than PSMA-PET fixed threshold for detecting csPCa.
引用
收藏
页码:887 / 896
页数:10
相关论文
共 36 条
  • [1] PI-RADS-Based Segmented Threshold of PSMA-PET SUVmax Is Better than Traditional Fixed Threshold for Diagnosing Clinically Significant Prostate Cancer Especially for PI-RADS 3 Lesions
    Xiaoli Meng
    Wenhui Ma
    Jingliang Zhang
    Zhiyong Quan
    Mingru Zhang
    Jiajun Ye
    Jun Shu
    Jing Ren
    Weijun Qin
    Fei Kang
    Jing Wang
    Molecular Imaging and Biology, 2023, 25 : 887 - 896
  • [2] Molecular and diffusion features for identification of clinically significant prostate cancer in PI-RADS 3 lesions
    Ajami, Tarek
    Han, Sunwoo
    Porto, Joao G.
    Kimbel, Isabella
    Szczotka, Zoe
    Guerard, Timothy
    VanderVeer-Harris, Nathan
    Ledesma, Braian R.
    Acosta, Patricia Castillo
    Kryvenko, Oleksandr N.
    Parekh, Dipen J.
    Stoyanova, Radka
    Reis, Isildinha M.
    Punnen, Sanoj
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2024, 42 (11) : 370e9 - 370e14
  • [3] PI-RADS upgrading as the strongest predictor for the presence of clinically significant prostate cancer in patients with initial PI-RADS-3 lesions
    Kwe, Jeremy
    Baunacke, Martin
    Boehm, Katharina
    Platzek, Ivan
    Thomas, Christian
    Borkowetz, Angelika
    WORLD JOURNAL OF UROLOGY, 2024, 42 (01)
  • [4] Considering Predictive Factors in the Diagnosis of Clinically Significant Prostate Cancer in Patients with PI-RADS 3 Lesions
    Natale, Caleb
    Koller, Christopher R.
    Greenberg, Jacob W.
    Pincus, Joshua
    Krane, Louis S.
    LIFE-BASEL, 2021, 11 (12):
  • [5] Assessment of PI-RADS v2 categories3 for diagnosis of clinically significant prostate cancer
    Patel, Nayana U.
    Lind, Kimberly E.
    Garg, Kavita
    Crawford, David
    Werahera, Priya N.
    Pokharel, Sajal S.
    ABDOMINAL RADIOLOGY, 2019, 44 (02) : 705 - 712
  • [6] A PI-RADS-Based New Nomogram for Predicting Clinically Significant Prostate Cancer: A Cohort Study
    Zhang, Yueyue
    Zhu, Guiqi
    Zhao, Wenlu
    Wei, Chaogang
    Chen, Tong
    Ma, Qi
    Zhang, Yongsheng
    Xue, Boxin
    Shen, Junkang
    CANCER MANAGEMENT AND RESEARCH, 2020, 12 : 3631 - 3641
  • [7] The use of 68Ga-PSMA PET/CT to stratify patients with PI-RADS 3 lesions according to clinically significant prostate cancer risk
    Yang, Jinhui
    Tang, Yongxiang
    Zhou, Chuanchi
    Zhou, Ming
    Li, Jian
    Hu, Shuo
    PROSTATE, 2023, 83 (05) : 430 - 439
  • [8] Assessment of PI-RADS v2 categories ≥ 3 for diagnosis of clinically significant prostate cancer
    Nayana U. Patel
    Kimberly E. Lind
    Kavita Garg
    David Crawford
    Priya N. Werahera
    Sajal S. Pokharel
    Abdominal Radiology, 2019, 44 : 705 - 712
  • [9] The function of Prostate Health Index in detecting clinically significant prostate cancer in the PI-RADS 3 population: a multicenter prospective study
    Zhou, Yongheng
    Fu, Qiang
    Shao, Zhiqiang
    Qi, Wenqiang
    Zhong, Minglei
    Lv, Guangda
    Jiang, Zhiwen
    Zhu, Meikai
    Wang, Wenfu
    Shi, Benkang
    Chen, Shouzhen
    Zhu, Yaofeng
    WORLD JOURNAL OF UROLOGY, 2023, 41 (2) : 455 - 461
  • [10] Biparametric MRI-based radiomics for prediction of clinically significant prostate cancer of PI-RADS category 3 lesions
    Lu, Feng
    Zhao, Yanjun
    Wang, Zhongjuan
    Feng, Ninghan
    BMC CANCER, 2025, 25 (01)